Received Oct 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2M7GR | — |
rash injection site; fever chills; This non-serious case was reported by a consumer and described the occurrence of injection site rash in a 60-year-old female patient who received Herpes zoster (Shingrix) (batch number 2M7GR) for prophylaxis. On 09-SEP-2025, the patient received Shingrix. On 10-SEP-2025, 1 days after receiving Shingrix, the patient experienced injection site rash (Verbatim: rash injection site) and fever chills (Verbatim: fever chills). On 13-SEP-2025, the outcome of the fever chills was resolved (duration 3 days). On 14-SEP-2025, the outcome of the injection site rash was resolved (duration 4 days). It was unknown if the reporter considered the injection site rash and fever chills to be related to Shingrix. It was unknown if the company considered the injection site rash and fever chills to be related to Shingrix. Additional Information: GSK Receipt Date: 17-SEP-2025 The reporter stated that, A 60-year-old female was received Shingrix on 09-SEP-2025, patient experienced rash injection site and fever chills on 10-SEP-2025. The symptoms of ash injection site and fever chill were not treated. Fever chills resolved on 13-SEP-2025 and injection site rash was resolved on 14-SEP-2025. Patient was not pregnant. The expiry date of Shingrix was reported as unknown and no other products reported.